Polarean Imaging plc has entered into an exclusive distribution agreement with DK Healthcare Co., Ltd. for the distribution of its innovative Xenon MRI platform in South Korea. This partnership, announced on November 24, 2025, marks Polarean’s second international distribution agreement and aims to enhance the Company’s presence in the Asia-Pacific market.
The collaboration with DK Healthcare, a prominent player in the South Korean diagnostic radiology sector, will facilitate the necessary regulatory approvals for the commercial launch of Polarean’s technology. Established in 1986 and headquartered in Seoul, DK Healthcare has built a solid reputation for delivering advanced imaging solutions and comprehensive support to medical facilities across Korea.
Christopher von Jako, Ph.D., CEO of Polarean, expressed enthusiasm about the partnership, highlighting the significance of South Korea’s focus on early detection and precision medicine. “We are delighted to partner with DK Healthcare, one of South Korea’s most respected medical imaging distributors, to expand access to our Xenon MRI platform,” he stated. This strategic move aligns with Polarean’s efforts to grow internationally through high-quality regional partners while its U.S. operations continue to promote domestic adoption.
The Xenon MRI technology offers a transformative approach to lung function assessment by visualizing ventilation and gas exchange in ways that traditional imaging cannot achieve. Joonhyuk Lee, CEO of DK Healthcare, emphasized the potential impact of this platform on respiratory care in South Korea. “We believe Xenon MRI will play a vital role in transforming respiratory care in South Korea through enhancing early detection and outcomes for patients with lung cancer, COPD, and beyond.”
Polarean Imaging aims to revolutionize pulmonary medicine through its non-invasive and radiation-free imaging solutions. The Company has developed the first and only hyperpolarized Xenon MRI inhaled contrast agent, known as XENOVIEW, which has received approval from the U.S. Food and Drug Administration. This technology aims to address the global unmet medical needs of over 500 million patients suffering from chronic respiratory diseases.
The partnership with DK Healthcare underscores Polarean’s commitment to expanding its global footprint. The collaboration will not only introduce advanced imaging technology to South Korea but also enhance the capabilities of medical professionals in diagnosing and treating respiratory conditions.
Polarean, founded in 2012, operates offices in Durham, NC, and London. The Company’s mission is to increase awareness and accessibility of its innovative XENOVIEW MRI technology, further strengthening its position in the competitive medical imaging landscape.
For additional information on Polarean Imaging and its products, please visit [www.polarean.com](http://www.polarean.com).
